GlassScriptPhysician profile
Whitney Potter
NPI 1215314794
$9,759.48
in general payments reported to CMS, 2019-2025
25 companies · $2,435 in 2025
The $2,435 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $371 · 2021: $2,569 · 2022: $1,511 · 2023: $1,322 · 2024: $1,375 · 2025: $2,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,093 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,093.39 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,758.02 | 2021-2025 | |
| Glaukos Corporation | $1,178.10 | 2020-2025 | Glaucoma Accessory Products, Istent Infinite, Idosetr |
| Alcon Vision LLC | $799.97 | 2019-2025 | Clareon, Clareon Panoptix Pro, Tryptyr |
| New World Medical,INC. | $782.07 | 2022-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Bausch & Lomb Americas INC. | $581.00 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Harrow Eye, LLC | $538.02 | 2023-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $511.92 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $442.88 | 2021-2023 | |
| Dompe US, INC. | $441.11 | 2021-2025 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $358.31 | 2021-2022 | |
| Ocular Therapeutix, INC. | $351.07 | 2022-2025 | Dextenza |
| Rxsight INC | $322.00 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $318.87 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $236.78 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $214.12 | 2024-2025 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $193.44 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $171.11 | 2021-2025 | Acthar |
| Eyevance Pharmaceuticals LLC | $159.75 | 2021-2023 | Tobradex St |
| Oyster Point Pharma, INC. | $135.50 | 2022-2024 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $63.25 | 2025 | Catalys System, Tecnis Iol |
| Rayner Intraocular Lenses Limited | $62.82 | 2023 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Allergan, INC. | $43.28 | 2020 | |
| Sight Sciences, INC. | $39.18 | 2022 | |
| Apellis Pharmaceuticals, INC. | $33.31 | 2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $23.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.